Victory Capital Management
ACIU icon

Victory Capital Management’s AC Immune ACIU Stock Holding History

Victory Capital Management’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-26,757
Closed -$277K – 1806
2017
Q1 		$277K Buy
26,757
+11,757
+78% +$144K ﹤0.01% 1373
2016
Q4 		$195K Hold
15,000
– – ﹤0.01% 1388
2016
Q3 		$247K Buy
+15,000
New +$259K ﹤0.01% 1351

Other funds holding ACIU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management's ACIU Position: Q2 2017 in Review

Victory Capital Management sold out of AC Immune (ACIU) in Q2 2017, closing a stake of 26,757 shares — an estimated $277K sold.

Victory Capital Management first reported a position in ACIU in Q3 2016 and held it in 3 quarters. The position peaked at $277K in Q1 2017. 17 funds tracked by Wall St. Rank hold ACIU as of Q2 2017.

  • Victory Capital Management reported no remaining AC Immune position as of Q2 2017 after selling out during the quarter.
  • Victory Capital Management sold 26,757 AC Immune shares in Q2 2017, an estimated $277K.
  • Victory Capital Management first reported a position in AC Immune in Q3 2016 and held it in 3 quarters.
  • Victory Capital Management's AC Immune position peaked at $277K in Q1 2017.
  • 17 funds tracked by Wall St. Rank held AC Immune as of Q2 2017.

Based on Victory Capital Management's 13F filing for Q2 2017, filed 7 Aug 2017.